Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 10 |
List of Tables | 10 | 1 |
List of Figures | 11 | 1 |
Introduction | 12 | 1 |
Global Markets Direct Report Coverage | 12 | 1 |
Cytomegalovirus (HHV-5) Infections Overview | 13 | 1 |
Therapeutics Development | 14 | 2 |
Pipeline Products for Cytomegalovirus (HHV-5) Infections Overview | 14 | 1 |
Pipeline Products for Cytomegalovirus (HHV-5) Infections Comparative Analysis | 15 | 1 |
Cytomegalovirus (HHV-5) Infections Therapeutics under Development by Companies | 16 | 2 |
Cytomegalovirus (HHV-5) Infections Therapeutics under Investigation by Universities/Institutes | 18 | 2 |
Cytomegalovirus (HHV-5) Infections Pipeline Products Glance | 20 | 4 |
Late Stage Products | 20 | 1 |
Clinical Stage Products | 21 | 1 |
Early Stage Products | 22 | 1 |
Unknown Stage Products | 23 | 1 |
Cytomegalovirus (HHV-5) Infections Products under Development by Companies | 24 | 3 |
Cytomegalovirus (HHV-5) Infections Products under Investigation by Universities/Institutes | 27 | 2 |
Cytomegalovirus (HHV-5) Infections Companies Involved in Therapeutics Development | 29 | 27 |
Adicet Bio, Inc. | 29 | 1 |
AIMM Therapeutics BV | 30 | 1 |
Astellas Pharma Inc | 31 | 1 |
Atara Biotherapeutics Inc | 32 | 1 |
AvidBiotics Corp | 33 | 1 |
Biotest AG | 34 | 1 |
Chimerix Inc | 35 | 1 |
China Biologic Products Inc | 36 | 1 |
CyTuVax BV | 37 | 1 |
Fate Therapeutics Inc | 38 | 1 |
GlaxoSmithKline Plc | 39 | 1 |
Hookipa Biotech AG | 40 | 1 |
Kadmon Corp LLC | 41 | 1 |
Laboratoires Thea SA | 42 | 1 |
Merck &Co Inc | 43 | 1 |
Microbiotix Inc | 44 | 1 |
Mymetics Corp | 45 | 1 |
Novartis AG | 46 | 1 |
Pfizer Inc | 47 | 1 |
Phoenix Biotechnology Inc | 48 | 1 |
Savoy Pharmaceuticals, Inc. | 49 | 1 |
Sigma-Tau SpA | 50 | 1 |
Themis Bioscience GmbH | 51 | 1 |
Trellis Bioscience Inc | 52 | 1 |
Vakzine Projekt Management GmbH | 53 | 1 |
VBI Vaccines Inc | 54 | 1 |
Vical Inc | 55 | 1 |
Cytomegalovirus (HHV-5) Infections Therapeutics Assessment | 56 | 10 |
Assessment by Monotherapy Products | 56 | 1 |
Assessment by Combination Products | 57 | 1 |
Assessment by Target | 58 | 2 |
Assessment by Mechanism of Action | 60 | 2 |
Assessment by Route of Administration | 62 | 2 |
Assessment by Molecule Type | 64 | 2 |
Drug Profiles | 66 | 90 |
AIC-387 Drug Profile | 66 | 1 |
AIC-476 Drug Profile | 67 | 1 |
AIC-813 Drug Profile | 68 | 1 |
AL-18 Drug Profile | 69 | 1 |
Antibody for Human Cytomegalovirus Infection Drug Profile | 70 | 1 |
ASP-0113 Drug Profile | 71 | 3 |
brincidofovir Drug Profile | 74 | 14 |
BT-084 Drug Profile | 88 | 1 |
Cellular Immunotherapy for Cytomegalovirus and Adenovirus Infections Drug Profile | 89 | 1 |
Cellular Immunotherapy for Cytomegalovirus Infections Drug Profile | 90 | 1 |
Cellular Immunotherapy for Cytomegalovirus Infections Drug Profile | 91 | 1 |
Cellular Immunotherapy for Cytomegalovirus Infections Drug Profile | 92 | 1 |
Cellular Immunotherapy for Cytomegalovirus Infections Drug Profile | 93 | 1 |
Cellular Immunotherapy for Cytomegalovirus Infections and GBM Drug Profile | 94 | 1 |
Cellular Immunotherapy for Infectious Disease Drug Profile | 95 | 1 |
Cellular Immunotherapy for Infectious Diseases Drug Profile | 96 | 1 |
Cellular Immunotherapy for Viral Infections Drug Profile | 97 | 1 |
Cellular Immunotherapy for Viral Infections Post-HSCT Drug Profile | 98 | 1 |
Cellular Immunotherapy to Target CMV Antigen for Cytomegalovirus Infections Drug Profile | 99 | 1 |
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections Drug Profile | 100 | 2 |
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections Drug Profile | 102 | 1 |
Cellullar Immunotherapy for Viral Infections and Fungal Infections Drug Profile | 103 | 1 |
CMX-669 Drug Profile | 104 | 1 |
CSJ-148 Drug Profile | 105 | 1 |
CyMVectin Drug Profile | 106 | 2 |
cytomegalovirus (virus like particle) vaccine Drug Profile | 108 | 1 |
Cytomegalovirus (virus like particle) vaccine Drug Profile | 109 | 1 |
Cytomegalovirus vaccine Drug Profile | 110 | 1 |
Cytomegalovirus vaccine Drug Profile | 111 | 1 |
Cytomegalovirus vaccine Drug Profile | 112 | 1 |
filociclovir Drug Profile | 113 | 2 |
ganciclovir Drug Profile | 115 | 1 |
Gene Therapy for Cytomegalovirus Infections Drug Profile | 116 | 1 |
HB-101 Drug Profile | 117 | 1 |
letermovir Drug Profile | 118 | 3 |
maribavir Drug Profile | 121 | 3 |
MBX-2168 Drug Profile | 124 | 1 |
Monoclonal Antibodies to Inhibit HLA-A2 for Cytomegalovirus Infections Drug Profile | 125 | 1 |
Monoclonal Antibody for Cytomegalovirus Infections Drug Profile | 126 | 1 |
Monoclonal Antibody to Agonize LTbR for CMV Infection Drug Profile | 127 | 1 |
Pentamer Drug Profile | 128 | 1 |
Peptides to Inhibit Heparan Sulfate for HHV-5 Infections Drug Profile | 129 | 1 |
PepVax Drug Profile | 130 | 2 |
ProTmune Drug Profile | 132 | 2 |
PTX-3 Drug Profile | 134 | 1 |
RBT-301 Drug Profile | 135 | 1 |
Recombinant Peptide for Infectious Diseases Drug Profile | 136 | 1 |
Recombinant Protein for CMV Drug Profile | 137 | 1 |
RKP-00156 Drug Profile | 138 | 1 |
Small Molecule for Cytomegalovirus Drug Profile | 139 | 1 |
Small Molecules for CMV Infections Drug Profile | 140 | 1 |
Small Molecules for CMV infections and Cancer Drug Profile | 141 | 1 |
Small Molecules to Activate Sirtuin for Viral Infections Drug Profile | 142 | 1 |
Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections Drug Profile | 143 | 1 |
Small Molecules to Inhibit Cyclin-Dependent Kinase 7 for Oncology, Inflammation and Infectious Diseases Drug Profile | 144 | 1 |
Small Molecules to Inhibit Na+/K+ ATPase for Human Cytomegalovirus Infections Drug Profile | 145 | 1 |
Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease Drug Profile | 146 | 1 |
Triplex Drug Profile | 147 | 2 |
TRL-345 Drug Profile | 149 | 1 |
V-160 Drug Profile | 150 | 1 |
VBI-1501A Drug Profile | 151 | 2 |
Viralym-C Drug Profile | 153 | 1 |
Viroprev Drug Profile | 154 | 1 |
VPM-2001 Drug Profile | 155 | 1 |
Cytomegalovirus (HHV-5) Infections Dormant Projects | 156 | 5 |
Cytomegalovirus (HHV-5) Infections Discontinued Products | 161 | 1 |
Cytomegalovirus (HHV-5) Infections Product Development Milestones | 162 | 14 |
Featured News &Press Releases | 162 | 1 |
Nov 03, 2016: Atara Bio Collaborating Investigators to Present Results from Phase 2 Trial of Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) at the American Society of Hematology (ASH) Annual Meeting 2016 | 162 | 1 |
Oct 28, 2016: Data from Phase 1 Trial of Triplex Vaccine for Control of Cytomegalovirus Published in Blood | 162 | 1 |
Oct 27, 2016: Results from Shire Phase 2 Study of Maribavir Showed Activity Against CMV Infection in Patients Undergoing Transplant | 163 | 2 |
Oct 19, 2016: Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint | 165 | 1 |
Oct 11, 2016: Atara Bio Receives Positive Opinion from EMA on Orphan Drug Designation for Allogeneic Cytomegalovirus (CMV)-specific Cytotoxic T Lymphocytes (CTL) for Treatment of CMV Infection in Patients with Impaired Immune Systems | 165 | 1 |
Sep 20, 2016: Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus Vaccine (ASP0113) in Kidney Transplant Patients | 166 | 1 |
Sep 20, 2016: VBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of its Preventative Cytomegalovirus Vaccine Candidate | 166 | 1 |
Sep 01, 2016: VBI Vaccines to Present at the Vaccine Congress | 167 | 1 |
Aug 22, 2016: VBI Vaccines to Continue Enrolling Participants in the Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate Following Successful Data Safety Monitoring Board Review | 168 | 1 |
Jul 20, 2016: Hookipa Biotech Initiates First-in-Human Study of Cytomegalovirus Vaccine | 168 | 1 |
Jun 23, 2016: VBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate | 169 | 1 |
Feb 20, 2016: Chimerix Announces Presentation of Detailed Results From Phase 3 SUPPRESS Trial at BMT Tandem Meetings | 170 | 2 |
Dec 28, 2015: Chimerix Announces Top-Line Results From Phase 3 SUPPRESS Trial of Brincidofovir | 172 | 1 |
Nov 05, 2015: Atara Bio to Present Data on CMV-CTL at the American Society of Hematology Annual Meeting 2015 | 173 | 1 |
Oct 22, 2015: Chimerix Initiates Phase 3 SUSTAIN and SURPASS Trials of Brincidofovir for Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients | 174 | 2 |
Appendix | 176 | 2 |
Methodology | 176 | 1 |
Coverage | 176 | 1 |
Secondary Research | 176 | 1 |
Primary Research | 176 | 1 |
Expert Panel Validation | 176 | 1 |
Contact Us | 176 | 1 |
Disclaimer | 177 | 1 |